Antimicrobial effects of clindamycin-loaded platelet-rich fibrin (PRF)

Anton Straub1, Maximilian Stapf2, Chiara Utz3

  • 1Department of Oral and Maxillofacial Plastic Surgery, University Hospital Würzburg, Pleicherwall 2, 97070, Würzburg, Germany. Straub_A@ukw.de.

PubMed
Abstract

Insights

Platelet-rich fibrin (PRF) effectively carries clindamycin (CLI), demonstrating its suitability as a bio-carrier. This finding supports PRF

Area of Science:

  • Biomaterials Science
  • Infectious Diseases
  • Oral and Maxillofacial Surgery

Background:

  • Platelet-rich fibrin (PRF) has shown potential as a carrier for antibiotics like ampicillin/sulbactam.
  • Clindamycin (CLI) is a commonly used antibiotic for various infections.

Purpose of the Study:

  • To evaluate if PRF can serve as a suitable bio-carrier for clindamycin (CLI).
  • To assess the concentration and antimicrobial efficacy of clindamycin within PRF membranes.

Main Methods:

  • PRF membranes were prepared from 36 patients receiving intravenous clindamycin.
  • Clindamycin concentrations in PRF were quantified using liquid chromatography-tandem mass spectrometry.
  • In vitro antimicrobial activity was tested against relevant bacteria using agar diffusion assays.

Main Results:

  • Mean clindamycin concentration in PRF membranes was 0.7 ± 0.4 μg/100 mg PRF.
  • Antimicrobial activity was observed against Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus mitis, Porphyromonas gingivalis, and Fusobacterium nucleatum.
  • Inhibition zones indicated effective antimicrobial action for both fresh and 24-hour stored PRF.

Conclusions:

  • Platelet-rich fibrin is a suitable bio-carrier for systemically administered clindamycin.
  • The clindamycin concentration in PRF is sufficient to target clinically relevant bacteria.
  • PRF holds potential for expanded applications in local antibiotic delivery for infection prevention in oral and maxillofacial surgery.

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
524
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K